[1]Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopec E, et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol, 2007, 45(1): 179-192.[2]Mokrousov I, Narvskaya O, Otten T, et al. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother, 2002, 46(5): 1417-1424.[3]Doustdar F, Khosravi a D, Farnia P, et al. Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran. Microb Drug Resist, 2008, 14(4): 273-279.[4]Mukaigawa J, Endoh M, Yanagawa Y, et al. Anti-drug pattern of drug-resistant Mycobacterium tuberculosis and analysis of mutation in drug-target genes. Kansenshogaku Zasshi, 2005, 79(6): 388-396.[5]崔运勇, 王峰, 刘小立, 等. 深圳市耐多药结核分枝杆菌流行株耐药基因序列分析. 中国防痨杂志, 2011, 33(5): 257-262.[6]李桂莲, 谢彤, 巨韩芳, 等. 天津市耐异烟肼或利福平的结核分枝杆菌相关基因突变特征. 中华结核和呼吸杂志, 2010, 33(6): 460-461.[7]McCammon MT, Gillette JS, Thomas DP, et al. Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis. Antimicrob Agents Chemother, 2005, 49(6): 2200-2209.[8]中国防痨协会基础专业委员会. 结核病诊断实验室检验规程. 北京:中国教育文化出版社,2006:52.[9]WHO. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva:World Health Organization, 2008.[10]Van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol, 1993, 31(2): 406-409.[11]Aslan G, Tezcan S, Serin M S, et al. Genotypic analysis of isoniazid and rifampin resistance in drug-resistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey. Jpn J Infect Dis, 2008, 61(4): 255-260.[12]Lee AS, Teo AS, Wong SY. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother, 2001, 45(7): 2157-2159.[13]Kiepiela P, Bishop K S, Smith AN, et al. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber Lung Dis, 2000, 80(1): 47-56.[14]Abe C, Kobayashi I, Mitarai S, et al. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol, 2008, 46(7): 2263-2268.[15]Dalla Costa ER, Ribeiro MO, Silva MS, et al. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol, 2009, 9(1):39-44.[16]王海英, 徐勇, 邓云峰, 等. 山东省耐利福平结核分枝杆菌rpoB基因突变的研究. 中国防痨杂志, 2005, 27(5): 289-292.[17]Huitric E, Werngren J, Jureen P, et al. Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother, 2006, 50(8): 2860-2862.[18]李国利,张灵霞,王倩,等. 结核分枝杆菌临床分离株利福平耐药表型及rpoB基因型分析.临床和实验医学杂志,2011,10(21):1649-1652.[19]Hwang HY, Chang CY, Chang LL, et al. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Taiwan. J Med Microbiol, 2003, 52(Pt 3): 239-245.[20]Heep M, Brandstatter B, Rieger U, et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol, 2001, 39(1): 107-110.[21]李桂莲, 王撷秀, 谢彤, 等. 药物外排泵基因表达与结核分枝杆菌耐药关系的探讨. 中华检验医学杂志, 2011, 34(7): 605-611. |